a Division of Cardiac Surgery , Johns Hopkins Hospital , Baltimore , MD , USA.
b Department of Physics & Astronomy , Johns Hopkins University , Baltimore , MD , USA.
Expert Rev Med Devices. 2017 May;14(5):383-392. doi: 10.1080/17434440.2017.1324293. Epub 2017 May 9.
Conventional synthetic vascular grafts are limited by the inability to remodel, as well as issues of patency at smaller diameters. Tissue-engineered vascular grafts (TEVGs), constructed from biologically active cells and biodegradable scaffolds have the potential to overcome these limitations, and provide growth capacity and self-repair. Areas covered: This article outlines the TEVG design, biodegradable scaffolds, TEVG fabrication methods, cell seeding, drug delivery, strategies to reduce wait times, clinical trials, as well as a 5-year view with expert commentary. Expert commentary: TEVG technology has progressed significantly with advances in scaffold material and design, graft design, cell seeding and drug delivery. Strategies have been put in place to reduce wait times and improve 'off-the-shelf' capability of TEVGs. More recently, clinical trials have been conducted to investigate the clinical applications of TEVGs.
传统的合成血管移植物受到不能重塑的限制，以及在较小直径下通畅性的问题。由生物活性细胞和可生物降解支架构建的组织工程血管移植物 (TEVG) 有可能克服这些限制，并提供生长能力和自我修复。涵盖领域：本文概述了 TEVG 设计、可生物降解支架、TEVG 制造方法、细胞接种、药物输送、减少等待时间的策略、临床试验，以及专家评论的 5 年展望。专家评论：随着支架材料和设计、移植物设计、细胞接种和药物输送的进步，TEVG 技术取得了重大进展。已经制定了策略来减少等待时间并提高 TEVG 的“即用型”能力。最近，已经进行了临床试验来研究 TEVG 的临床应用。
